Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IND. SWIFT vs MANGALAM DRUGS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IND. SWIFT MANGALAM DRUGS IND. SWIFT/
MANGALAM DRUGS
 
P/E (TTM) x 3.4 -8.6 - View Chart
P/BV x - 1.0 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 IND. SWIFT   MANGALAM DRUGS
EQUITY SHARE DATA
    IND. SWIFT
Mar-23
MANGALAM DRUGS
Mar-23
IND. SWIFT/
MANGALAM DRUGS
5-Yr Chart
Click to enlarge
High Rs15173 8.5%   
Low Rs795 6.8%   
Sales per share (Unadj.) Rs75.9235.2 32.3%  
Earnings per share (Unadj.) Rs4.80.8 599.2%  
Cash flow per share (Unadj.) Rs10.17.7 130.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-130.196.0 -135.5%  
Shares outstanding (eoy) m54.1615.83 342.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.10.6 24.5%   
Avg P/E ratio x2.2166.8 1.3%  
P/CF ratio (eoy) x1.017.3 6.1%  
Price / Book Value ratio x-0.11.4 -5.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m5722,118 27.0%   
No. of employees `000NANA-   
Total wages/salary Rs m637346 184.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m4,1103,723 110.4%  
Other income Rs m1194 2,718.8%   
Total revenues Rs m4,2283,727 113.4%   
Gross profit Rs m1,026255 402.1%  
Depreciation Rs m287110 260.9%   
Interest Rs m598128 468.7%   
Profit before tax Rs m26022 1,176.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m09 0.0%   
Profit after tax Rs m26013 2,050.2%  
Gross profit margin %25.06.9 364.2%  
Effective tax rate %042.6 0.0%   
Net profit margin %6.30.3 1,857.0%  
BALANCE SHEET DATA
Current assets Rs m2,7342,066 132.3%   
Current liabilities Rs m9,3631,654 566.2%   
Net working cap to sales %-161.311.1 -1,456.6%  
Current ratio x0.31.2 23.4%  
Inventory Days Days1151 9,842.0%  
Debtors Days Days929456 203.6%  
Net fixed assets Rs m3,7581,530 245.6%   
Share capital Rs m108158 68.4%   
"Free" reserves Rs m-7,1551,361 -525.6%   
Net worth Rs m-7,0471,520 -463.8%   
Long term debt Rs m4,031188 2,148.1%   
Total assets Rs m6,4923,596 180.5%  
Interest coverage x1.41.2 122.3%   
Debt to equity ratio x-0.60.1 -463.2%  
Sales to assets ratio x0.61.0 61.2%   
Return on assets %13.23.9 339.0%  
Return on equity %-3.70.8 -442.1%  
Return on capital %-28.48.8 -324.5%  
Exports to sales %68.80-   
Imports to sales %5.325.7 20.5%   
Exports (fob) Rs m2,827NA-   
Imports (cif) Rs m217958 22.7%   
Fx inflow Rs m2,9471,078 273.4%   
Fx outflow Rs m313978 32.0%   
Net fx Rs m2,634100 2,628.1%   
CASH FLOW
From Operations Rs m730395 184.8%  
From Investments Rs m-293-222 132.4%  
From Financial Activity Rs m-466-166 280.2%  
Net Cashflow Rs m-297 -389.0%  

Share Holding

Indian Promoters % 55.6 50.3 110.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.1 -  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 44.4 49.7 89.4%  
Shareholders   14,219 18,610 76.4%  
Pledged promoter(s) holding % 42.8 18.1 236.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IND. SWIFT With:   SUN PHARMA    DIVIS LABORATORIES    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on IND. SWIFT vs MANGALAM DRUGS

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

IND. SWIFT vs MANGALAM DRUGS Share Price Performance

Period IND. SWIFT MANGALAM DRUGS S&P BSE HEALTHCARE
1-Day 9.82% -1.01% 1.18%
1-Month -1.59% -23.05% -0.75%
1-Year 165.52% -6.97% 61.82%
3-Year CAGR 59.78% -3.87% 18.16%
5-Year CAGR 28.15% 10.47% 19.79%

* Compound Annual Growth Rate

Here are more details on the IND. SWIFT share price and the MANGALAM DRUGS share price.

Moving on to shareholding structures...

The promoters of IND. SWIFT hold a 55.6% stake in the company. In case of MANGALAM DRUGS the stake stands at 50.3%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of IND. SWIFT and the shareholding pattern of MANGALAM DRUGS.

Finally, a word on dividends...

In the most recent financial year, IND. SWIFT paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.

MANGALAM DRUGS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.

You may visit here to review the dividend history of IND. SWIFT, and the dividend history of MANGALAM DRUGS.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.